V

ertex Pharmaceuticals on Wednesday selected two cystic fibrosis drugs to advance into late-stage clinical trials as part of different triple-combination regimens. The decision was based on new clinical data, also disclosed Wednesday, showing large improvements in lung function for patients with a type of cystic fibrosis that is genetically resistant to all treatments now on the market.

If the two new drugs reach the market, Vertex would be able to successfully treat the underlying cause of cystic fibrosis in roughly 90 percent of the 75,000 patients worldwide, up from roughly half.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy